Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01460602
Recruitment Status : Withdrawn (Investigator has relocated to MD Anderson)
First Posted : October 27, 2011
Last Update Posted : September 1, 2020
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Glenn Mills, Louisiana State University Health Sciences Center Shreveport

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma.

Condition or disease Intervention/treatment Phase
Follicular Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma Drug: MTD of Velcade, Nipent and Rituxan established in Part 1 Phase 1 Phase 2

Detailed Description:

Number of Subjects: During the Phase 1 part of the study as many as 15 subjects may be enrolled, based on the dose escalation scheme; the actual number of subjects enrolled will depend on the dose level at which the maximum tolerated dose (MTD) is established.

During the Phase 2 part of the study, approximately 15 subjects will be enrolled in order to obtain a total 30 response-evaluable subjects.

Study Objectives:

The primary objectives of this study are:

• Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy.

The secondary objectives of this study are to:

  • Determine the MTD of VELCADE and Nipent in combination with Rituxan (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy
  • Evaluate the safety and tolerability of VNR
  • Determine the time to response
  • Determine duration of response
  • Determine the time to progression (TTP)
  • Determine the progression free survival (PFS) rate
  • Determine the 1-year survival
  • Determine overall survival (OS)
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Actual Study Start Date : May 2010
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part 1: establish MTD
Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
 Drug: MTD of Velcade, Nipent and Rituxan established in Part 1

One of the following dose levels will be chosen and used in Part 2:

  1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Experimental: Part 2: The MTD from Part 1
During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
 Drug: MTD of Velcade, Nipent and Rituxan established in Part 1

One of the following dose levels will be chosen and used in Part 2:

  1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
  4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]
    Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48

  2. ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]
    Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48


Secondary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]
    Number of participants with adverse events as a measure of safety and tolerability

  2. Rate of progression of disease [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]
    Summary data on time to progression of disease of study subjects


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Voluntary written informed consent.
  2. Male or female subject 18 years of age and older
  3. Karnofsky Performance Status (KPS) score of 50%. ECOG Performance Status score greater than 2.
  4. Histologically confirmed follicular Grade 1-3a, marginal zone or mantle cell NHL.
  5. Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.
  6. Bi-dimensionally measurable disease with at least 1 lesion 2 cm in a single dimension
  7. Hematologic, hepatic, and renal function parameters.
  8. Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs
  9. Expected survival of 3 months
  10. Accepted birth control methods during treatment and for 12 months after completion of treatment.

Exclusion Criteria:

  1. Follicular lymphoma Grade 3b
  2. History of allergy to any of the study medications, their analogues, murine proteins, or excipients in the various formulations
  3. Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment
  4. Serum creatinine 2.5 mg/dL within 14 days before enrollment.
  5. Absolute neutrophil count (ANC) < 1,000/L, platelet count < 70,000/L within 14 days before enrollment
  6. Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT/SGPT]) > 2 x the upper limit of normal (ULN), total bilirubin > 3 ULN
  7. Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6 months)
  8. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosurea or mytomycin-C)
  9. Prior lymphoma vaccine therapy within 12 months to Study Day 1
  10. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1
  11. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1
  12. Known history of hepatitis or hepatic disease.
  13. Presence of central nervous system (CNS) lymphoma
  14. Known history of HIV infection or AIDS
  15. Histologic transformation (Follicular or Marginal zone to diffuse large B cell lymphoma [DLBCL]
  16. Presence of pleural or peritoneal effusion with positive cytology for lymphoma
  17. Another primary malignancy requiring active treatment
  18. Serious non-malignant disease (e.g., congestive heart failure [CHF], hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions (including psychiatric), which would compromise protocol objectives n the opinion of the Investigator and/or Sponsor
  19. New York Heart Association Class III or IV (Appendix D) cardiac disease
  20. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
  21. Female subject who is pregnant or currently breast-feeding
  22. Received other investigational drugs with 14 days before enrollment
  23. Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460602


Locations
Layout table for location information
United States, Louisiana
LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center
Shreveport, Louisiana, United States, 71103
Sponsors and Collaborators
Louisiana State University Health Sciences Center Shreveport
Millennium Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Francesco Turturro, MD LSUHSC-S
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Glenn Mills, Professor of Medicine, Louisiana State University Health Sciences Center Shreveport
ClinicalTrials.gov Identifier: NCT01460602    
Other Study ID Numbers: X05266
First Posted: October 27, 2011    Key Record Dates
Last Update Posted: September 1, 2020
Last Verified: July 2020
Keywords provided by Glenn Mills, Louisiana State University Health Sciences Center Shreveport:
Lymphoma
Follicular
Marginal Zone
Mantle Cell
Velcade
bortezomib
 Nipent
pentastatin
Rituxan
rituximab
Turturro
Shreveport
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Mantle-Cell
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
 Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Rituximab
Bortezomib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents